RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure has commenced its first Phase II clinical trial to evaluate the efficacy of the company’s OBE101 drug candidate for weight loss in obese patients. The study is a double-blinded, placebo-controlled dose-ranging study in about 280 subjects over a period of three months. The study will be carried out at 20 medical sites across the U.S.
